Drugs /

zirconium zr 89-labeled anti-ca19-9 monoclonal antibody 5b1

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
A radioimmunoconjugate comprised of the recombinant human monoclonal antibody against the carbohydrate antigen sialyl-Lewis a (carbohydrate antigen 19-9; CA19-9) conjugated to the chelator desferrioxamine (DFO) and labeled with the radioisotope zirconium Zr 89 (Zr 89), with radioisotopic activity and potential use as an imaging agent in positron emission tomography (PET). The antibody moiety of zirconium Zr 89 anti-CA19-9 monoclonal antibody 5B1 targets and binds to CA19-9 expressing-tumor cells. Upon binding, internalization and proteolysis, the radioisotope moiety may be detected using PET, thus allowing imaging and quantification of CA19-9-expressing tumor cells. CA19-9, overexpressed on a number of different tumor cell types, plays a key role in tumor cell survival and metastasis.

Clinical Trials

View Clinical Trials for zirconium zr 89-labeled anti-ca19-9 monoclonal antibody 5b1

Zirconium zr 89-labeled anti-ca19-9 monoclonal antibody 5b1 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating zirconium zr 89-labeled anti-ca19-9 monoclonal antibody 5b1, 1 is phase 1 (0 open).

Pancreatic ductal adenocarcinoma is the most common disease being investigated in zirconium zr 89-labeled anti-ca19-9 monoclonal antibody 5b1 clinical trials [2].

Drug Details

Synonyms [2]:
mvt-2163
Drug Categories [2]:
Therapeutic antibodies
NCIT ID [1]:
C126332

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.